Tumour tissue proteomics
Available on demand
Learn more about how the Evosep One has been used in identifying the proteins present in tumor tissues and discovering biomarkers used to detect or monitor the presence of cancer. These findings pave the way for translating research into clinical applications, including the development of new diagnostic tests, targeted therapies, and improved treatment protocols.
Meet the Speakers
Deep topographic proteomics of a human brain tumour
Roman Fischer, associate professor and Head of discovery proteomics facility, University of Oxford
The presentation will explore the development and application of systematic spatial proteome analysis in human tumour tissue with view of resolving the spatial context of the tumour proteome. Further, the presentation will cover proteome clustering with obvious visual queues such as tumour border or vascularisation, but also show proteome based mapping and discovery of new tumour areas, tracking extracellular matrix or immune cell markers.
Proteogenomic Characterization of Chemotherapy Response in Muscle Invasive Bladder Cancer
Matthew Holt, Laboratory Director, Baylor College of Medicine
Only one quarter of patients with muscle invasive urothelial bladder cancer (MIBC) gain approximately 5% improvement in 5-year overall survival from standard of care cisplatin-based neoadjuvant chemotherapy (NAC). Characterizing MIBC poses challenges due to inherent muscle tissue infiltration. Proteogenomic profiling of high tumor content samples from 60 patients recapitulated previously established TCGA genomic and transcriptomic signatures. Notably, proteomic and phosphoproteomic profiles mirror RNAseq subtypes but diverge significantly in key regulatory pathways. We leveraged our recent SEPepQuant algorithm to identify isoforms and isoform families specific to chemotherapy resistance and validated these results with targeted proteomics. Our findings reinforce established MIBC subtypes, while offering new mechanistic insights into chemotherapy resistance.